ID

41052

Beschrijving

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01088984

Link

https://clinicaltrials.gov/show/NCT01088984

Trefwoorden

  1. 17-06-20 17-06-20 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

17 juni 2020

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Leukemia NCT01088984

Eligibility Leukemia NCT01088984

  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01088984
Criteria
Beschrijving

Criteria

the patient has histologically proven acute lymphocytic leukemia (all) or acute myeloid leukemia (aml) that has relapsed or is refractory to the last regimen, and the patient is without alternative curative therapy.
Beschrijving

Acute lymphocytic leukemia | Leukemia, Myelocytic, Acute | Recurrent disease | Unresponsive to Treatment | Curative treatment Alternative Lacking

Datatype

boolean

Alias
UMLS CUI [1]
C0023449
UMLS CUI [2]
C0023467
UMLS CUI [3]
C0277556
UMLS CUI [4]
C0205269
UMLS CUI [5,1]
C1273390
UMLS CUI [5,2]
C1523987
UMLS CUI [5,3]
C0332268
the patient's last myelosuppression therapy ended at least 2 weeks before the first dose of study drug.
Beschrijving

Myelosuppressive Therapy Ended

Datatype

boolean

Alias
UMLS CUI [1,1]
C1513793
UMLS CUI [1,2]
C1272693
nonhematologic acute toxic effects of prior therapy have resolved to grade 2 or less according to national cancer institute (nci) common terminology criteria for adverse events (ctcae).
Beschrijving

Toxic effect Due to Prior Therapy | Toxic effect resolved CTCAE Grades

Datatype

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514463
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C1514893
UMLS CUI [2,3]
C1516728
the patient has adequate liver function with bilirubin values less than or equal to 1.5 times the upper limit of normal (uln) and aspartate aminotransferase (ast) and alanine aminotransferase (alt) values less than or equal to 5 times the age-appropriate uln.
Beschrijving

Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Datatype

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
the patient has adequate renal function with serum creatinine values less than 2 times uln.
Beschrijving

Renal function | Creatinine measurement, serum

Datatype

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0201976
the patient has karnofsky or lansky performance status of 60 or greater. patients older than 16 years of age will be scored according to the karnofsky scale and patients 16 years of age or younger will be scored according to the lansky scale.
Beschrijving

Karnofsky Performance Status | Lansky Play-Performance Status | Age

Datatype

boolean

Alias
UMLS CUI [1]
C0206065
UMLS CUI [2]
C1522275
UMLS CUI [3]
C0001779
the patient may have had hematopoietic stem cell transplantation.
Beschrijving

Hemopoietic stem cell transplant

Datatype

boolean

Alias
UMLS CUI [1]
C0472699
women of childbearing potential (not surgically sterile) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
Beschrijving

Childbearing Potential Contraceptive methods

Datatype

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
Beschrijving

Male sterilization Absent Sexual Abstinence | Male sterilization Absent Barrier Contraception | Male fertility Sexual Abstinence | Male fertility Barrier Contraception

Datatype

boolean

Alias
UMLS CUI [1,1]
C0024559
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0036899
UMLS CUI [2,1]
C0024559
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0004764
UMLS CUI [3,1]
C1955321
UMLS CUI [3,2]
C0036899
UMLS CUI [4,1]
C1955321
UMLS CUI [4,2]
C0004764
the patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.
Beschrijving

Protocol Compliance

Datatype

boolean

Alias
UMLS CUI [1]
C0525058
key exclusion criteria:
Beschrijving

Exclusion Criteria Main

Datatype

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
the patient has any active, uncontrolled systemic infection, severe concurrent disease, or symptomatic untreated central nervous system (cns) involvement.
Beschrijving

Sepsis Uncontrolled | Comorbidity Severe | Central Nervous System Involvement Symptomatic Untreated

Datatype

boolean

Alias
UMLS CUI [1,1]
C0243026
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0205082
UMLS CUI [3,1]
C4050309
UMLS CUI [3,2]
C0231220
UMLS CUI [3,3]
C0332155
the patient has evidence of active graft versus host disease.
Beschrijving

Graft-vs-Host Disease

Datatype

boolean

Alias
UMLS CUI [1]
C0018133
the patient has a known human immunodeficiency virus (hiv) infection.
Beschrijving

HIV Infection

Datatype

boolean

Alias
UMLS CUI [1]
C0019693
the patient has active hepatitis b or hepatitis c infection.
Beschrijving

Hepatitis B | Hepatitis C

Datatype

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
the patient is a pregnant or lactating woman. any women becoming pregnant during the study will be withdrawn from the study immediately.
Beschrijving

Pregnancy | Breast Feeding

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
the patient has any serious uncontrolled medical or psychological disorder that would impair the ability of the patient to receive study drug.
Beschrijving

Disease Serious Uncontrolled | Mental disorders Serious Uncontrolled | Investigational New Drugs Receive Impaired

Datatype

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0205318
UMLS CUI [2,1]
C0004936
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C0205318
UMLS CUI [3,1]
C0013230
UMLS CUI [3,2]
C1514756
UMLS CUI [3,3]
C0221099
the patient has any condition that places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
Beschrijving

Condition Study Subject Participation Status At risk | Condition Interferes with Interpretation Research data

Datatype

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1444641
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0459471
UMLS CUI [2,4]
C0681873
the patient has received any other investigational agent within 30 days of study entry.
Beschrijving

Investigational New Drugs Recent

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0332185
the patient has known hypersensitivity to bendamustine or mannitol.
Beschrijving

Hypersensitivity Bendamustine | Mannitol allergy

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0525079
UMLS CUI [2]
C0571922

Similar models

Eligibility Leukemia NCT01088984

  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01088984
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Acute lymphocytic leukemia | Leukemia, Myelocytic, Acute | Recurrent disease | Unresponsive to Treatment | Curative treatment Alternative Lacking
Item
the patient has histologically proven acute lymphocytic leukemia (all) or acute myeloid leukemia (aml) that has relapsed or is refractory to the last regimen, and the patient is without alternative curative therapy.
boolean
C0023449 (UMLS CUI [1])
C0023467 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
C0205269 (UMLS CUI [4])
C1273390 (UMLS CUI [5,1])
C1523987 (UMLS CUI [5,2])
C0332268 (UMLS CUI [5,3])
Myelosuppressive Therapy Ended
Item
the patient's last myelosuppression therapy ended at least 2 weeks before the first dose of study drug.
boolean
C1513793 (UMLS CUI [1,1])
C1272693 (UMLS CUI [1,2])
Toxic effect Due to Prior Therapy | Toxic effect resolved CTCAE Grades
Item
nonhematologic acute toxic effects of prior therapy have resolved to grade 2 or less according to national cancer institute (nci) common terminology criteria for adverse events (ctcae).
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0600688 (UMLS CUI [2,1])
C1514893 (UMLS CUI [2,2])
C1516728 (UMLS CUI [2,3])
Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
the patient has adequate liver function with bilirubin values less than or equal to 1.5 times the upper limit of normal (uln) and aspartate aminotransferase (ast) and alanine aminotransferase (alt) values less than or equal to 5 times the age-appropriate uln.
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Renal function | Creatinine measurement, serum
Item
the patient has adequate renal function with serum creatinine values less than 2 times uln.
boolean
C0232804 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Karnofsky Performance Status | Lansky Play-Performance Status | Age
Item
the patient has karnofsky or lansky performance status of 60 or greater. patients older than 16 years of age will be scored according to the karnofsky scale and patients 16 years of age or younger will be scored according to the lansky scale.
boolean
C0206065 (UMLS CUI [1])
C1522275 (UMLS CUI [2])
C0001779 (UMLS CUI [3])
Hemopoietic stem cell transplant
Item
the patient may have had hematopoietic stem cell transplantation.
boolean
C0472699 (UMLS CUI [1])
Childbearing Potential Contraceptive methods
Item
women of childbearing potential (not surgically sterile) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Male sterilization Absent Sexual Abstinence | Male sterilization Absent Barrier Contraception | Male fertility Sexual Abstinence | Male fertility Barrier Contraception
Item
men not surgically sterile or who are capable of producing offspring must practice abstinence or use a barrier method of birth control, and must agree to continue use of this method for the duration of treatment and for 30 days after the end of treatment.
boolean
C0024559 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0036899 (UMLS CUI [1,3])
C0024559 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0004764 (UMLS CUI [2,3])
C1955321 (UMLS CUI [3,1])
C0036899 (UMLS CUI [3,2])
C1955321 (UMLS CUI [4,1])
C0004764 (UMLS CUI [4,2])
Protocol Compliance
Item
the patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.
boolean
C0525058 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Sepsis Uncontrolled | Comorbidity Severe | Central Nervous System Involvement Symptomatic Untreated
Item
the patient has any active, uncontrolled systemic infection, severe concurrent disease, or symptomatic untreated central nervous system (cns) involvement.
boolean
C0243026 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009488 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C4050309 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0332155 (UMLS CUI [3,3])
Graft-vs-Host Disease
Item
the patient has evidence of active graft versus host disease.
boolean
C0018133 (UMLS CUI [1])
HIV Infection
Item
the patient has a known human immunodeficiency virus (hiv) infection.
boolean
C0019693 (UMLS CUI [1])
Hepatitis B | Hepatitis C
Item
the patient has active hepatitis b or hepatitis c infection.
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
the patient is a pregnant or lactating woman. any women becoming pregnant during the study will be withdrawn from the study immediately.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Disease Serious Uncontrolled | Mental disorders Serious Uncontrolled | Investigational New Drugs Receive Impaired
Item
the patient has any serious uncontrolled medical or psychological disorder that would impair the ability of the patient to receive study drug.
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0004936 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C0013230 (UMLS CUI [3,1])
C1514756 (UMLS CUI [3,2])
C0221099 (UMLS CUI [3,3])
Condition Study Subject Participation Status At risk | Condition Interferes with Interpretation Research data
Item
the patient has any condition that places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data.
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0459471 (UMLS CUI [2,3])
C0681873 (UMLS CUI [2,4])
Investigational New Drugs Recent
Item
the patient has received any other investigational agent within 30 days of study entry.
boolean
C0013230 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Hypersensitivity Bendamustine | Mannitol allergy
Item
the patient has known hypersensitivity to bendamustine or mannitol.
boolean
C0020517 (UMLS CUI [1,1])
C0525079 (UMLS CUI [1,2])
C0571922 (UMLS CUI [2])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial